Prosecution Insights
Last updated: October 25, 2026
Application No. 18/703,558

METHODS FOR GENETIC ANALYSIS OF TEXTILES COMPRISING G. BARBADENSE

Non-Final OA §101§103
Filed
Apr 22, 2024
Priority
Oct 21, 2021 — provisional 63/270,346 +1 more
Examiner
BAUSCH, SARAE L
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Applied DNA Sciences, Inc.
OA Round
1 (Non-Final)
30%
Grant Probability
At Risk
1-2
OA Rounds
1y 3m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants only 30% of cases
30%
Career Allowance Rate
182 granted / 613 resolved
-30.3% vs TC avg
Strong +45% interview lift
Without
With
+45.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
50 currently pending
Career history
677
Total Applications
across all art units

Statute-Specific Performance

§101
22.0%
-18.0% vs TC avg
§103
20.6%
-19.4% vs TC avg
§102
21.3%
-18.7% vs TC avg
§112
29.9%
-10.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 613 resolved cases

Office Action

§101 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of group I, claims 1-15 in the reply filed on 08/03/2026 is acknowledged. Claims 16-18 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/03/2026. Claims 1-15 are under examination. Drawings The drawings are acceptable. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-15 are rejected under 35 U.S.C. 101 because the claimed invention is directed to abstract idea without significantly more. Claim 1 and claim 15 recite an abstract idea that is a mental process. The recitation of generating a variable amplicon length polymorphism profile (VALP) from the amplicons and comparing the generated VALP with a G94 variable amplicon length polymorphism profile, thereby determining whether the mature cotton fiber includes G94 recite in claim 1 is a mental process and thereby verifying the authenticity of the mature cotton fiber from the manufactured article as including a fiber from G94 recited in claim 15 are mental processes. Neither the claim nor the specification set forth limiting definitions for generating and comparing and the claims do not set forth how generating or comparing is accomplished. The broadest reasonable interpretation of generating and comparing is a step that comprises mental process step which could be practice in the mind. Additionally the step of generating a profile can encompass data analysis process which can be accomplished mentally by evaluating data and critical thinking process wherein one mentally reads information from results. The step of comparing includes evaluating data and critical thinking process wherein one mentally reads information in a database or report and compares the data. The claims additionally set forth providing mature cotton fiber from a manufactured article, extracting DNA from the fiber, amplifying DNA using a primer set of SEQ ID NO 1 and SEQ ID NO 2 to produce one or more amplicons. This judicial exception is not integrated into a practical application because the steps in addition to the judicial exceptions are data gathering steps that do not apply or integrate the judicial exception in any way. The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the steps in addition to the judicial exception are data gathering steps recited at a high level of generality employing techniques that were well-established, routine and conventional at the time of the invention. The courts have recognized that amplifying and sequencing nucleic acid sequences is among the well-understood, routine, conventional activity in the life science arts when claimed in a merely generic matter. Here, the claims include steps of providing a mature cotton fiber from a manufactured article, extracting DNA from a mature cotton fiber, amplifying a portion of DNA using SEQ ID NO 1 and SEQ ID NO 2. Prior to the invention, Liang et al. (US Patent 8940485 B2) taught providing mature cotton fibers, extracting genomic DNA from cotton fibers, amplifying region by PCR (see and teaches detection of amplicons by capillary electrophoresis (see fig 1 and column 7, lines 1-5). Mishra teaches SEQ ID NO 1 and SEQ ID NO 2 for validation of fiber quality (see pg. 353, BNL1531 primers). This evidences that these steps were conventional at the time of the invention. Furthermore, Liang teaches a detecting physical characteristic such as a different sequence (see column 3, lines 1-12). Claims 2-4 limits the DNA, which is a field of use limitation and does not amount to significantly more. Liang further teaches nuclear, mitochondrial, and chloroplast DNA (see column 4, lines 38-41). Claims 5-7 limits the judicial exception of how the generated VALP is obtained. Claims 8, limits PCR to real-time PCR, which was well known, routine and conventional in the art. Liang teaches real-time PCR (see column 5, lines 10-12). Claim 9-11, further comprises additional detectable physical characteristics, which were routine in the art. Liang teaches detectable physical characterizes (see column 3, lines 1-12). Claims 12-14 further limit the sample, which is a field of use limitation and does not amount to significantly more. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-15 are rejected under 35 U.S.C. 103 as being unpatentable over Liang (US 8940485 B2) in view of Mishra (Int. J. Scientific Research in Knowledge, 1(9), pp 349-357, 2013) and Gurmessa (Proceedings of National Conference on Crop Improvement and Management Research, 2019, pp. 67-78) Liang teaches for identifying cotton cultivar by collecting mature cotton fibers from a sample, extracting genomic DNA from the collected mature cotton fibers, amplifying DNA with PCR based techniques, and analyzing amplified product to distinguish between a first cotton cultivar and a second cotton cultivar. Liang teaches the first cotton cultivar is G. barbadense and the second cotton cultivar is G. barbadense (see column 2, lines 47-55). Liang teaches amplifying using a set of specific primers that target sequence polymorphism between the two cultivars (See column 2, lines 58-61). Liang teaches SSR primers to detect markers with varying DNA length polymorphisms (see column 6, lines 48-50). Liang teaches that primer sequences are only exemplary and are not meant to be limiting in scope for verifying cotton fibers (see column 9, lines 1-5). With regard to claims 2-4, Liang teaches genomic DNA comprises nuclear DNA, mitochondrial DNA and chloroplast DNA (see column 4, lines 38-41). With regard to claims 5 and 7, Liang teaches analyzing amplification products by detecting size of provide by capillary electrophoresis or gel electrophoresis (see column 3, lines 13-17). With regard to claim 8, Liang teaches amplification includes real-time PCR (see column 5, lines 10-12) With regard to claims 9-11, Liang teaches the targeted sequences have different detectable physical characteristics and different sequence compositions (see column 3, lines 1-12). Liang teaches probes that bind to a target sequence (see column 4, lines 56-64). With regard to claims 12 and 13, Liang teaches the sample is a textile item or raw cotton material (see column 2, lines 55-57). With regard to claim 14, Liang teaches textiles include yarn and fabric (see column 5, lines 43-45). Liang does not primers consisting or comprising of SEQ ID NO 1 and SEQ ID NO 2. Liang does not teach G94. Mishra teaches amplification of genomic DNA of cotton genotypes. Mishra teaches SSR primers. Mishra teaches primers for BNL1531, which consists of SEQ ID NO 1 and SEQ ID NO 2 (see table 2, pg. 353). Gurmessa teaches genetic diversity among G. barbadense. Gurmessa teaches evaluation of G94 (See table 1). Gurmessa teaches use of SSR markers to discriminate germplasm, including G94 (see pg. 77). Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to improve the method of identifying cultivars of G. barbadense by amplifying DNA extracted from cotton fiber, as taught by Liang to include additional SSR markers as taught by Mishra and identify and verify authencity of known cultivars of G. barbadense, including Giza 94 as taught by Gurmessa to improve the method of Liang. The ordinary artisan would have been motivated with a reasonable expectation of success to improve the method of identifying cultivars of G. barbadense of Liang and include additional known primers for SSR markers, including primers taught by Mishra consisting of SEQ ID NO 1 and SEQ ID NO 2 because Liang teaches additional primers could be used in the method and the method is not limited to the primers disclosed by Liang. The ordinary artisan would have been motivated with a reasonable expectation of success to improve the method of identifying cultivars of G. barbadense of Liang and include analysis of other known cultivars of G. Barbadense, including G94 for authenticity because Liang teaches the method allows for distinguishing between two different cultivars of G. Barbadense. In performing the method of identifying G94 as taught by Liang and Gurmessa with primers taught in the art by Mishra, one would have generated polymorphic profile with peaks at 115bp, 121bp, 126 bp, and 128bp as these peaks would have resulted in performing amplification of G94 using BNL1531 primer pair taught by Mishra. Conclusion No claims are allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAE L BAUSCH whose telephone number is (571)272-2912. The examiner can normally be reached M-F 9a-4p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SARAE L BAUSCH/ Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Apr 22, 2024
Application Filed
Oct 15, 2026
Non-Final Rejection mailed — §101, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760365
Clinical and Molecular Prognostic Markers for Liver Transplantation
4y 6m to grant Granted Oct 13, 2026
Patent 12742209
METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR
3y 6m to grant Granted Sep 22, 2026
Patent 12716098
GENETIC DIAGNOSTIC TOOL FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
3y 9m to grant Granted Aug 25, 2026
Patent 12704506
MICROBIAL ANALYSIS WITHOUT CELL PURIFICATION
5y 4m to grant Granted Aug 11, 2026
Patent 12686890
CRISPR-CAS14A RESPONSE PHOTOELECTROCHEMICAL SENSING DETECTION METHOD AND KIT FOR DETECTING T2 TOXIN
3y 6m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
30%
Grant Probability
75%
With Interview (+45.0%)
3y 9m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 613 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month